Clinical-stage biopharmaceutical company Viking Therapeutics Inc (NASDAQ:VKTX) saw its shares rocket as broker H.C. Wainwright, which initiated coverage on the firm with a Buy recommendation. The brokerage firm has set the target price of US$6 it reported in a research report released on Thursday, sending shares more than 63% higher to US$2.33.
www.proactiveinvestors.com/companies/news/...erage-124556.html
Pipeline:
www.vikingtherapeutics.com/pipeline/overview/
www.proactiveinvestors.com/companies/news/...erage-124556.html
Pipeline:
www.vikingtherapeutics.com/pipeline/overview/